Puma Biotechnology Added to NASDAQ Biotechnology Index
December 14 2017 - 4:15PM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, has been selected for addition to the NASDAQ Biotechnology
Index (NASDAQ: NBI) as part of the NBI’s annual re-ranking of
biotechnology and pharmaceutical companies listed on The NASDAQ
Stock Market® (NASDAQ) that meet NBI’s eligibility criteria. Puma
will be added to the NBI effective prior to market open on Monday,
December 18, 2017.
The NASDAQ Biotechnology Index is a modified market
capitalization weighted index that is designed to track the
performance of a set of securities listed on The NASDAQ Stock
Market that are classified as either biotechnology or
pharmaceutical according to the Industry Classification Benchmark
(ICB) and is re-ranked annually in December.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a
focus on the development and commercialization of innovative
products to enhance cancer care. The Company in-licenses the global
development and commercialization rights to three drug candidates —
PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
Neratinib, oral was approved by the U.S. Food and Drug
Administration in July 2017 for the extended adjuvant treatment of
adult patients with early stage HER2-overexpressed/amplified breast
cancer, following adjuvant trastuzumab-based therapy, and is
marketed in the United States as NERLYNX® (neratinib) tablets.
NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Further information about Puma Biotechnology can be found at
www.pumabiotechnology.com.
Forward-Looking Statements:
This press release contains forward-looking statements that
involve risks and uncertainties that could cause the Company's
actual results to differ materially from the anticipated results
and expectations expressed in these forward-looking statements.
These statements are based on current expectations, forecasts and
assumptions, and actual outcomes and results could differ
materially from these statements due to a number of factors, which
include, but are not limited to, the fact that the Company has only
recently commenced commercialization and shipment of its only FDA
approved product; the Company’s dependence upon the commercial
success of NERLYNX (neratinib); the Company’s history of operating
losses and its expectation that it will continue to incur losses
for the foreseeable future; risks and uncertainties related to the
Company’s ability to achieve or sustain profitability; the
Company’s ability to predict its future prospects and forecast its
financial performance and growth; failure to obtain sufficient
capital to fund the Company’s operations; the effectiveness of
sales and marketing efforts; the Company’s ability to obtain FDA
approval or other regulatory approvals in the United States or
elsewhere for other indications for neratinib or other product
candidates; the challenges associated with conducting and enrolling
clinical trials; the risk that the results of clinical trials may
not support the Company’s drug candidate claims; even if approved,
the risk that physicians and patients may not accept or use the
Company’s products; the Company’s reliance on third parties to
conduct its clinical trials and to formulate and manufacture its
drug candidates; risks pertaining to securities class action,
derivative and defamation lawsuits; the Company’s dependence on
licensed intellectual property; and the other risk factors
disclosed in the periodic and current reports filed by the Company
with the Securities and Exchange Commission from time to time,
including the Company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2017. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. The Company assumes no obligation
to update these forward-looking statements, except as required by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171214006309/en/
Puma Biotechnology, Inc.Alan H. Auerbach or Mariann Ohanesian,+1
424 248
6500info@pumabiotechnology.comir@pumabiotechnology.comorRusso
PartnersDavid Schull or Amiad Finkelthal, +1 212 845
4200david.schull@russopartnersllc.comamiad.finkelthal@russopartnersllc.com
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Sep 2023 to Sep 2024